Morning Trend | Junshi Biosciences (1877.HK) is under pressure again, can the weak sector welcome a capital inflow?

Junshi Biosciences (1877.HK) closed yesterday with overall performance still sluggish, dominated by bearish sentiment. The stock price has continuously fallen below key short-term moving averages, especially oscillating below the 5-day and 10-day moving averages, with a spreading atmosphere of market sell-off. The trading volume during the session continued to expand, reflecting accelerated capital withdrawal and showing that confidence within the sector has been significantly impacted. Recently, the overall heat of the biopharmaceutical sector has notably declined, with continuous negative news such as stricter regulations on innovative drugs and prolonged approval cycles, leading to a lack of effective positive catalysts in the market and further intensifying risk aversion. In the past week, Junshi Biosciences has not announced any significant new drug advancements or external collaborations. The entire biopharmaceutical industry is experiencing a scarcity of news, and the "involution" within the industry is intensifying, causing investors to adopt a more conservative outlook for the future. Technically, the MACD shows a clear death cross, with bearish arrangements in the daily and weekly moving average systems, and short-term support levels continuously declining. Especially after the stock price fell below the 20-day and 30-day moving averages, there have been no significant signs of rebound, making it difficult to confirm the current stage bottom. Yesterday, there was little buying interest in the market, and the net outflow of funds throughout the day was substantial, reflecting a strong wait-and-see sentiment among major funds. Currently, the short-term environment shows a weak structure, and risk exposure should not be taken lightly. The actual situation in the market indicates that some institutions have actively reduced their positions, and some short-term speculative funds have quickly taken profits and exited, leading to a significant decrease in trading activity. If there are significant drug data releases or leading companies in the sector stabilize after a decline, Junshi Biosciences may expect to see follow-up fluctuations, but currently, there is a lack of behavioral capital turning point signals